Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 2Phase NA 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 109NIH 30INDUSTRY 14NETWORK 6OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

fludarabine 7Cyclophosphamide 7Nivolumab 6Metformin 4pembrolizumab 3fludarabine phosphate 3Radiotherapy 3Melphalan 3Ipilimumab 3Interleukin-2 3Injections 3S 1 (combination) 2Irinotecan 2tremelimumab 1selinexor 1parsaclisib 1olaparib 1nabiximols 1ivarmacitinib 1durvalumab 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1carfilzomib 1apatorsen 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Topotecan 1Rituximab 1Radiosurgery 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × OTHER_GOV × Radiation × Clear all
NCT05088889 2023-11-28

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Sheba Medical Center

Phase 1 Unknown
10 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡